Table 1.

Baseline characteristics of the Western European cohort

Characteristic	nab-P + Gem (n=38)	Gem (n=38)	All patients in Western Europe (n=76)	ITT population (N=861)*
Age, median (range), years	59.5 (37–77)	66.0 (42–80)	63.0 (37–80)	63.0 (27–88)
≥65 years, %	29	61	45	42
Male, %	53	39	46	58
KPS, %
90–100	74	82	78	60
70–80	24	18	21	40
Primary tumor location, %
Head	39	27a	33	43
Body	47	49a	48	31
Tail	13	24a	19	25
Site(s) of metastasis, %
Liver	87	84	86	84
Lung	24	45	34	39
No of metastatic sites, %
1	8	8	8	6
2	53	47	50	47
≥3	39	45	42	46
Previous Whipple, %	0	5	3	7
Biliary stent, %	8	8	8	17

Notes:

^aEvaluable n=37.

^*From N Engl J Med, Von Hoff DD, Ervin T, Arena FP, et al, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, 69, 1691–1703. Copyright © (2013) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.⁸

Abbreviations: Gem, gemcitabine; ITT, intention-to-treat; KPS, Karnofsky performance status; nab-P, nab-paclitaxel.